Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques

6 abstracts

Abstract
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.
Org: Gustave Roussy Cancer Center, University of Pennsylvania, National Cancer Center Hospital East, Kashiwa, Japan, Seoul National University Bundang Hospital, Yonsei University College of Medicine,
Abstract
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.
Org: Aix-Marseille University CHU Timone, APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques, CNRS UMR 5309-INSERM U1209, INP, Inst Neurophysiopathol,
Abstract
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Org: Hôpitaux Nord-Ouest, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).
Org: Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University, Versailles, France, Institut Curie, Saint Cloud, France, Univ Rouen Normandie, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Org: Aix Marseille University - Assistance Publique Hopitaux De Marseille, APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, CNRS UMR 5309-INSERM U1209, CRCM,
Abstract
Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.
Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,